A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection

Autor:	Brad McRae, David W. Borhani, Biqin Li, Kurt Ritter, Gavin C. Hirst, David J. Calderwood, Wendy Waegell, Sheldon E. Ratnofsky, Michael Friedman, A.K.W. Leung
Rok vydání:	2004
Předmět:	Graft Rejection Models Molecular Clinical Biochemistry Administration Oral Pharmaceutical Science Pharmacology Biochemistry Inhibitory Concentration 50 Mice Structure-Activity Relationship Dogs Pharmacokinetics Oral administration Immunopathology Drug Discovery medicine Animals Humans Hypersensitivity Delayed Molecular Biology Molecular Structure biology Chemistry Organic Chemistry Biological activity medicine.disease Transplant rejection Mice Inbred C57BL Transplantation Pyrimidines Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Delayed hypersensitivity Enzyme inhibitor Models Animal Immunology Microsomes Liver biology.protein Heart Transplantation Interleukin-2 Pyrazoles Molecular Medicine Immunosuppressive Agents
Zdroj:	Bioorganic & Medicinal Chemistry Letters. 14:2613-2616
ISSN:	0960-894X
DOI:	10.1016/j.bmcl.2004.02.101
Popis:	We have identified the pyrazolo[3,4-d]pyrimidine A-420983 (compound 7) as a potent inhibitor of lck. A-420983 exhibits oral efficacy in animal models of delayed-type hypersensitivity and organ transplant rejection.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::580da66de5527b2d655e007519b924e5 https://doi.org/10.1016/j.bmcl.2004.02.101 Zobrazit plný text záznamu Full Text from ScienceDirect